Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.

Min-Wei Yang,Xue-Liang Fu,Yong-Sheng Jiang,Xiao-Jing Chen,Ling-Ye Tao,Jian-Yu Yang,Yan-Miao Huo,Wei Liu,Jun-Feng Zhang,Pei-Feng Liu,Qiang Liu,Rong Hua,Zhi-Gang Zhang,Yong-Wei Sun,De-Jun Liu

DOI: https://doi.org/10.3748/wjg.v25.i14.1684

IF: 5.374

2019-01-01

World Journal of Gastroenterology

Abstract:BACKGROUND Recently, more and more studies have demonstrated the pivotal role of programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway in the immune evasion of tumors from the host immune system. However, the role of PD-1/PD-L1 pathway in gastric neuroendocrine carcinomas (G-NECs) remains unknown. AIM To investigate the expression of PD-1/PD-L1 and role of PD-1/PD-L1 pathway in G-NECs, which occur rarely but are highly malignant and clinically defiant. METHODS We investigated the expression of PD-L1 on tumor cells and PD-1(+), CD8(+), and FOXP3(+) T cell infiltration by immunohistochemistry in 43 resected G-NEC tissue specimens. The copy number alterations of PD-L1 were assessed by qRT-PCR. RESULTS Most of the G-NECs tumor cells exhibited a near-uniform expression pattern of PD-L1, while some showed a tumor-stromal interface enhanced pattern. Of the 43 G-NECs, 21 (48.8%) were classified as a high PD-L1 expression group, and the high expression of PD-L1 was associated with poor overall survival (OS). The high expression of PD-L1 was correlated with abundant PD-1(+) tumor infiltrating lymphocytes (TILs) instead of CD8(+) TILs and FOXP3(+) regulatory T cells (Tregs). Our analysis also suggested that the infiltration of CD8(+) TILs tended to be a favorable factor for OS, although the difference did not reach the statistical significance (P = 0.065). Meanwhile, PD-L1 was significantly overexpressed in cases with copy number gain as compared with those without. CONCLUSION Our data demonstrated for the first time that high expression of PD-L1 in G-NECs is associated with a poor prognosis, while the high expression may be due to the copy number variation of PD-L1 gene or stimulation of TILs. These results provide a basis for the immunotherapy targeting PD-1/PD-L1 pathway in G-NECs.